The pharmaceutical industry's commitment to patient safety and treatment efficacy hinges on the quality and purity of the raw materials and intermediates used in drug manufacturing. For Ticagrelor, a crucial medication in managing acute coronary syndromes, (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride (CAS: 1156491-10-9) stands as a key intermediate where stringent quality control is non-negotiable.

(1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride is not merely a chemical ingredient; it is a precisely engineered molecule designed to facilitate the synthesis of Ticagrelor with the correct stereochemistry and a high degree of purity. The designation (1R,2S) refers to the specific spatial arrangement of atoms around chiral centers, which is critical for the drug's ability to bind to its target receptor and exert its therapeutic effect. Any deviation in this stereochemistry or a lack of purity can lead to reduced efficacy, potential side effects, or difficulties in the drug's formulation and regulatory approval.

Manufacturers typically specify an assay purity of ≥98.0% for this intermediate. This high purity level minimizes the presence of unwanted by-products or isomers that could complicate subsequent synthesis steps or contaminate the final Active Pharmaceutical Ingredient (API). The physical characteristic of being a white to yellow powder is often associated with high-purity organic compounds, though subtle color variations can occur based on manufacturing nuances. Proper storage in a cool, well-ventilated environment is essential to maintain this purity and prevent degradation.

The global demand for Ticagrelor means that reliable sourcing of its intermediates is a strategic priority for pharmaceutical companies. Manufacturers like NINGBO INNO PHARMCHEM CO.,LTD. play a vital role by ensuring that (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride is produced under strict quality management systems. When businesses look to buy this intermediate, they seek suppliers who can demonstrate consistent quality across batches, provide comprehensive analytical data, and maintain a stable supply chain. The competitive pricing offered by Chinese chemical manufacturers, coupled with their advanced production capabilities, makes them attractive partners for global pharmaceutical firms.

The integrity of the supply chain for critical intermediates like this cyclopropanamine derivative is paramount. Pharmaceutical companies must perform thorough due diligence when selecting suppliers, verifying their compliance with international quality standards and their capacity to meet demand. Partnering with a reputable chemical supplier China offers can provide the necessary assurance of quality, leading to a more robust and efficient manufacturing process for Ticagrelor.

In conclusion, the quality and purity of (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride are fundamental to the successful production of Ticagrelor. By understanding these requirements and partnering with experienced manufacturers like NINGBO INNO PHARMCHEM CO.,LTD., the pharmaceutical industry can continue to deliver safe and effective treatments for cardiovascular diseases.